» Articles » PMID: 16686710

Comparison of the Clinical Outcome After Hormonal Therapy for Prostate Cancer Between Japanese and Caucasian Men

Overview
Journal BJU Int
Specialty Urology
Date 2006 May 12
PMID 16686710
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the impact of race on the effectiveness of hormonal therapy in patients with prostate cancer, by comparing the outcomes of Caucasian men (CM) and Japanese-American men (JAM) treated with hormonal therapy at one institution.

Patients And Methods: Fifty-nine CM and 105 JAM with prostate cancer were treated with hormonal therapy at The Queen's Medical Center in Honolulu. Age, stage, Gleason score, race, and pretreatment PSA levels were abstracted. The Kaplan-Meier method was used to construct overall and cause-specific survival curves, which were compared using log-rank statistics. These factors were assessed as to their interdependence and correlation with the clinical course using a Cox proportional hazards regression model.

Results: Although there were no statistical differences in patient background, JAM who had received hormonal treatment had a better outcome than CM for overall and cause-specific survival rate (P = 0.001 and 0.036, respectively). Race was one of the significant prognostic factors in the multivariate analysis (P = 0.03). The findings suggest a difference in the effectiveness of hormonal therapy for prostate cancer in JAM living in Hawaii compared to CM.

Conclusions: There were marked racial differences in clinical outcome after hormonal therapy between JAM and CM. A prospective study with more patients might be necessary to elucidate the differential effectiveness of hormonal therapy for prostate cancer in different races, especially between Japanese and Caucasians.

Citing Articles

Efficacy of androgen receptor signaling inhibitors in combination with androgen deprivation therapy for castration-sensitive metastatic prostate cancer: a retrospective analysis in a Japanese cohort.

Taga M, Sasaki T, Higashi S, Kimura S, Sawada A, Tsuchiyama K Int J Clin Oncol. 2024; 30(2):351-357.

PMID: 39692835 PMC: 11785660. DOI: 10.1007/s10147-024-02670-5.


Improved prognosis of de novo metastatic prostate cancer after an introduction of life-prolonging agents for castration-resistant prostate cancer.

Tanegashima T, Shiota M, Terada N, Saito T, Yokomizo A, Kohei N Int J Clin Oncol. 2024; 30(3):551-558.

PMID: 39688742 DOI: 10.1007/s10147-024-02681-2.


Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A study.

Shiota M, Nemoto S, Ikegami R, Tatarano S, Kamoto T, Kobayashi K BJC Rep. 2024; 2(1):69.

PMID: 39516672 PMC: 11523954. DOI: 10.1038/s44276-024-00093-3.


Novel Treatment Strategies for Low-Risk Metastatic Castration-Sensitive Prostate Cancer.

Iwamoto H, Hori T, Nakagawa R, Kano H, Makino T, Naito R Cancers (Basel). 2024; 16(18).

PMID: 39335169 PMC: 11430633. DOI: 10.3390/cancers16183198.


The Omission of Upfront Treatment Intensification Does Not Adversely Affect Oncological Outcomes in a Subset of Castration-Highly Sensitive Metastatic Prostate Cancer.

Fujimoto N, Nagata Y, Shiota M, Minato A, Tomisaki I, Harada K In Vivo. 2024; 38(5):2328-2334.

PMID: 39187338 PMC: 11363787. DOI: 10.21873/invivo.13698.